DENTAL-MONITORING/LOUM
Dental Monitoring has acquired Loum, "the digital assistant for patients and healthcare professionals.” Founded in 2017, Loum's objective is to ensure that patients perceive their healthcare positively, and not as a burden. Their innovative developments, in particular an application designed to improve the patient experience, complements Dental Monitoring’s expansive suite of AI-driven tools. The app implements a playful and dynamic system that facilitates the doctor-patient relationship and allows patients to engage fully with their treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200505005871/en/
"We are delighted with the acquisition of Loum, which allows us to integrate complementary skills into our teams and meet the expectations of patients and their doctors worldwide. We are coordinating a robust solution and collaborating with a team of skilled colleagues who will enhance our AI-powered platform with new strategies and an innovative approach. Ultimately, we want to design a more playful version of our patient application, and through Loum’s gamification approach, which allows for careful monitoring of treatment, this is an angle that we are now addressing," says Philippe Salah, CEO of the Dental Monitoring.
"Placing gaming at the heart of the healthcare protocol not only brings a little lightness to the patient’s journey, but also makes any follow-up care much more appealing, accessible, and more likely to be followed,” explains Michaël Sutter, CEO of Loum.
"Joining Dental Monitoring is great news for us and our customers. We now offer them the possibility of benefitting from a broader range of cutting-edge solutions for the management of their patients’ care, while continuing to provide them with personalized and local support. This integration is also an accelerator in terms of innovation and is therefore in line with a product offering that remains at the forefront of market expectations. We are delighted to bring our vision of the patient journey and to partner with those who share our taste for service and excellence," announced Michaël Sutter, CEO, and Clément Coicault, COO of Loum.
###
About Dental Monitoring:
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals and improve the care they provide their patients.
Dental Monitoring solutions are created to assist dental professionals throughout their patients’ journeys by:
● Simplifying the connection between dental professionals and patients
● Facilitating follow-ups and providing an easier virtual experience during treatment
● Improving treatment stability and results over time
Dental Monitoring is present across Europe, the United States and Asia Pacific. It has 250 employees and 5 offices (Paris, Austin - Texas, London, Hong Kong and Sydney).
Dental Monitoring is changing the way dental and orthodontic professionals care for patients. If you would like more information about Loum and this acquisition, or about the Dental Monitoring’s full suite of tele dentistry solutions, please visit www.dental-monitoring.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom